Anaptysbio: Peers

The FY2025 (Jun) proxy of Anaptysbio names 15 peer companies for pay. Among Anaptysbio and these peers, CEO pay was 2nd highest of 3 and total shareholder return was the highest of 3.

2nd highest of 3in Anaptysbio and its pay peers, FY2025 (Jun) by CEO pay:

$4.7M$8.5M

1st highest of 3in Anaptysbio and its pay peers, FY2025 (Jun) by total shareholder return:

$84$156

Pay peer group, FY2025 (Jun) proxy

Kymera Therapeutics
Kura Oncology
ALX OncologyNot disclosedNot disclosed
Allogene TherapeuticsNot disclosedNot disclosed
Apogee TherapeuticsNot disclosedNot disclosed
ArcellxNot disclosedNot disclosed
Astria TherapeuticsNot disclosedNot disclosed
Centessa PharmaceuticalsNot disclosedNot disclosed
IGM BiosciencesNot disclosedNot disclosed
Janux TherapeuticsNot disclosedNot disclosed
Jasper TherapeuticsNot disclosedNot disclosed
Pilant TherapeuticsNot disclosedNot disclosed
Replimune GroupNot disclosedNot disclosed
XencorNot disclosedNot disclosed
iTeos TherapeuticsNot disclosedNot disclosed
15 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.